To facilitate the investigation of hepatitis B virus (HBV) sequence variation, we recently established a method for functional analysis of PCR-amplified full-length HBV genomes. This study aimed at estimating the number of mutations introduced during amplification of genomes from samples from patients with low levels of viremia and their influence on replication and antigen expression. Wild-type HBV DNA template molecules in concentrations like those present in samples from patients with very low levels of viremia were amplified, sequenced (30 kb total), and functionally tested. We found that Taq polymerase and a Taq-Pwo polymerase mixture introduced an average of 5.7 and 3.1 mutations per genome, respectively, corresponding to polymerase error rates of 12.1 ؋ 10 ؊5 and 6.0 ؋ 10 ؊5 . One of 8 genomes (12%) amplified with Taq polymerase, but 7 of 17 genomes amplified with Taq-Pwo polymerases (41%), remained replication competent. All replicationcompetent genomes expressed HBs and HBe antigens and had an average of only 0.9 mutations per genome. In contrast, replication-defective genomes had an average of 5.4 mutations, which frequently also disturbed viral antigen expression. From these data we conclude that many of the replication-competent HBV genomes from a clinical specimen will retain their replication and antigen expression phenotypes even after extensive amplification with Taq-Pwo polymerases. Because replication competence is highly sensitive to random mutations, it is the best marker for the identification of HBV genomes with few or no PCR-introduced mutations.
Hepatitis B virus (HBV) sequence variability is increasingly recognized as a factor which modulates the course and outcome of HBV infection. Variants with disturbed hepatitis B e antigen (HBeAg) synthesis (24, 30) , large deletions in the nucleocapsid gene (12, 20) , or novel hepatocyte nuclear factor 1 binding sites in the core promoter (14, 25) were found to be associated with severe liver disease. Furthermore, mutations in the major antigenic determinant of the hepatitis B surface antigen (HBsAg) are probably responsible for the failure of immunization (4, 21) , and mutations in the virus polymerase protein render HBV resistant to therapy with nucleoside analogs (1, 19, 38) .
To facilitate the analysis of natural HBV isolates, we recently established a method for efficient PCR amplification of full-length HBV genomes which allows the isolation of a large number of genomes even from clinical samples from patients with low levels of viremia (13) . Only a single cloning step is required before the phenotype of an amplified genome can be tested by transfection into hepatoma cell lines. Alternatively, the cloning step can be omitted and the phenotype of the whole HBV genome population can be studied by directly transfecting the amplified genomes. Application of this method to structural analysis of HBV in clinical samples has already led to the identification of novel and highly diverse types of genomes with deletions of up to 2 kb in serum and liver samples (15, 31) .
To extend knowledge of the molecular features of natural virus isolates, other research groups have also established fulllength genome PCRs for human immunodeficiency virus type 1 (6, 8, 28, 29) , human T lymphotropic virus type 1 (34) , human papillomavirus (33) , hepatitis A virus (35, 36) , hepatitis C virus (35) , tick-borne encephalitis virus (11) , simian virus 40 (18) , and simian foamy virus (17) by taking advantage of long-range PCR conditions described recently (2) . A major concern noted in these studies as well as in our previous study is the introduction of artificial sequence errors during PCR (7) which may alter the phenotypes of the amplified genomes or even render them defective. In two studies this problem was addressed by sequencing amplified genomes of human papillomavirus (33) and human immunodeficiency virus type 1 (28) , which revealed an error frequency of about one error per 700 bases. The functional consequences of PCR-introduced mutations have so far been analyzed only in a recent study with PCR-amplified simian virus 40 genomes which found no functional deficiencies in the amplified clones (18) . However, the consequences of random mutations in HBV may be quite different. Therefore, prior to application of our PCR method to clinical samples we aimed in this study to evaluate the frequency and possible functional relevance of PCR-introduced mutations and to elucidate the optimal amplification system. Because problems with artificial mutations are particularly likely to arise if virus genomes are present in small amounts and require a high number of cycles, the test conditions were chosen appropriately. A few wild-type molecules in concentrations like those present in samples from patients with low levels of viremia were extensively amplified in different PCR systems, and the replication competence as well as the antigen expression of the amplified genomes was tested. Furthermore, a large number of amplified and cloned genomes were sequenced, the error frequencies were correlated with the functional pheno-merized strand with an error introduced in this cycle is P gen /2) and is used as the template in the next duplication cycle. After repeating this procedure n times (n ϭ number of duplication cycles) the likelihood that a genome has accumulated k mutations (0 Յ k Յ n) is described by the binomial distribution b(k;n; P gen /2). The mean number of mutations that accumulate per genome ( gen ) after n cycles is therefore given by the equation gen ϭ nP gen /2. Division of this equation by the nucleotide number of the HBV genome reveals the relation pos ϭ nP pos /2, where pos is the mean number of mutations that accumulate per nucleotide position and P pos is the error rate of the polymerase (errors per polymerized position) (7) . pos corresponds to the experimentally determined mean error frequency f (mutations per bases sequenced), and n was calculated by using the equation 2 n ϭ N f /N i , where N i is the initial template number and N f is the final copy number at the end of the PCR (both estimated from the mass and the molecular weight of the template and the PCR product). For calculation of P pos the equations were combined as P pos ϭ 0.6 ϫ f/log 10 (N f /N i ).
RESULTS
Influence of the type of DNA polymerase on PCR sensitivity. To determine which PCR system can be used for amplification of HBV genomes in sera from patients with low levels of viremia, defined copy numbers of plasmid-integrated HBV genomes were amplified with Pwo polymerase, which possesses proofreading activity (9) , Taq polymerase, which lacks proofreading activity (37) , and a Taq-Pwo polymerase mixture. The Pwo polymerase did not amplify less than 10 5 template molecules to a level detectable in an ethidium bromide-stained gel (Fig. 1A) . In contrast, reactions with Taq polymerase and TaqPwo polymerases efficiently amplified as few as 10 2 and 10 molecules, respectively (Fig. 1A) . To confirm these enzyme type-dependent differences in sensitivity, a PCR kinetic was performed with approximately 10 5 to 10 6 HBV virion DNA molecules as a template. The same set of enzymes as described above and the proofreading activity-possessing Pfu polymerase were used. Pwo and Pfu polymerases did not amplify the HBV virion DNA to levels detectable in an ethidium bromidestained gel even after 35 cycles, whereas Taq and Taq-Pwo polymerases produced a signal after 25 cycles (Fig. 1B) . These data indicate that amplification of HBV genomes from sera from patients with low levels of viremia requires Taq polymerase either alone or in combination with a thermostable polymerase with proofreading activity.
Influence of PCR-introduced mutations on the phenotypes of the amplified HBV genomes. The impact of PCR-introduced mutations was studied by extensive amplification of wild-type HBV genomes with both PCR systems which efficiently amplify HBV genomes and by functional testing of the amplified genomes as follows. From a cloned dimeric wild-type HBV genome, 900 and 90 molecules were amplified with Taq polymerase and Taq-Pwo polymerase mixture, respectively. An aliquot of the PCR products was cloned, and 8 Taq polymerase-amplified and 17 Taq-Pwo polymerase-amplified HBV genomes were randomly selected for functional analysis. After transfection of these genomes into HuH7 hepatoma cells, core particle-associated replicative HBV DNA was analyzed by Southern blotting and the secretion of HBsAg and HBeAg into the cell culture supernatant was determined by enzyme immunoassays.
Only 1 of the 8 Taq polymerase-amplified genomes (12%) was replication competent ( Fig. 2A and 3A ), whereas 7 of the 17 Taq-Pwo polymerase-amplified HBV genomes (41%) produced replicative HBV DNA in amounts comparable to that of the nonamplified wild-type genome ( Fig. 2B and 3B ). In contrast to the replication level, expression and secretion of HBsAg and HBeAg were much less frequently affected. Most of the Taq polymerase-amplified genomes and all of the Taq-Pwo polymerase-amplified genomes produced HBsAg at about the wild-type level (Fig. 3) . Similarly, 87% of the Taq polymeraseamplified genomes and 65% of the Taq-Pwo polymerase-amplified genomes efficiently produced HBeAg (Fig. 3 ). All ge- nomes which showed the authentic replication phenotype also expressed HBsAg and HBeAg at preamplification levels, whereas genomes with defects in replication frequently also had defects in antigen production (Table 1) . Since many genomes in clinical samples may be naturally defective in replication, we wondered whether a fraction of replication-competent genomes similar to that in the PCR test system is obtained with HBV DNA from patients. Therefore, 10 2 to 10 4 HBV genomes (as estimated by PCR) from sera of eight patients with fulminant hepatitis (32) were amplified with Taq-Pwo polymerases, cloned, and analyzed by transfection. Of 35 genomes tested, 24 (68%) were replication competent. This fraction is even larger than that obtained after the amplification of cloned wild-type genomes, indicating that the predominant virus population in the sera of these patients was replication competent. Taken together, after extensive amplification, as required for sera from patients with very low levels of viremia, the fraction of HBV genomes that exhibit the original phenotype of replication and antigen expression is about 40% if the PCR is performed with Taq-Pwo polymerase mixture. Taq polymerase alone produces a much larger fraction of defective genomes. The replication competence of a genome correlates with intact HBsAg and HBeAg expression.
Number and type of mutations introduced during PCR. To elucidate which and how many mutations accumulate during PCR and whether the number differs between genomes which showed the authentic phenotype and those which were rendered defective during PCR, a total of 30 kb of the amplified genomes was sequenced (Table 2) . Taking the data of all analyzed genomes together, those with the authentic phenotype had an average of 0.9 mutations whereas the defective ones had an average of 5.4 mutations ( Table 1) . Nearly all of the mutations (27 of 32) were transitions, usually T3C or A3G (Table 2) , which are specific for Taq polymerase (37). They frequently led to amino acid changes in at least one HBV reading frame and created a translational stop codon in the polymerase (P) and nucleocapsid (C) genes of genomes Taq-2 and Taq/Pwo-16, respectively. The latter mutations explain the replication defects of these genomes as well as the lack of HBeAg expression of genome Taq/Pwo-16 (Fig. 3B) . Because the defective genomes Taq-1, Taq/Pwo-14, and Taq/Pwo-15 lack amino acid changes in the nucleocapsid protein, those in the polymerase protein are most likely responsible for the replication defect (Table 2) . Taken together, the data indicate a correlation between the number of PCR-introduced mutations and the phenotypes of the amplified genomes. In defective genomes six times more mutations accumulated than in those which retained the authentic phenotype. The results also show that the random introduction of only a few mutations into a HBV genome can render it replication defective.
Determination of the polymerase error rate. The fidelity of polymerases is usually determined in assays which are based on one polymerization reaction or a few PCR cycles (7). However, the fidelity of Taq polymerase may be different if the reaction runs for a large number of cycles. This may be due, for example, to a change in the reaction conditions on which the fidelity of Taq polymerase strongly depends (7) . Therefore, we calculated the error rate of Taq polymerase and Taq-Pwo polymerase mixture in the 40-cycle full-length PCR. Based on the number of initial template molecules, the number of final reaction products, and the number of mutations found per number of bases sequenced, the error rate of Taq polymerase was determined to be 12.1 ϫ 10 Ϫ5 misincorporations per polymerized nucleotide and that of the Taq-Pwo polymerase mixture was determined to be 6.0 ϫ 10 Ϫ5 (Table 3 ). The calculated error rate of Taq polymerase agrees well with several published values ranging from 8.9 ϫ 10 Ϫ5 to 13.4 ϫ 10 Ϫ5 (2, 3, 37), which indicates no decrease in fidelity during full-length PCR. The combination of Pwo polymerase with Taq polymerase improved the fidelity of polymerization twofold, which is close to the threefold increase previously determined with a lacI-based assay (9) .
Functional analysis of amplified HBV genomes without cloning: optimization and influence of PCR on the HBV phenotype. The HBV full-length PCR also allows functional analysis of the amplified genomes by transfection without prior cloning (13) . This technique had not been tested with HBV DNA from samples from patients with low levels of viremia because a single PCR did not yield sufficient DNA for transfection. However, when the 3.2-kb PCR products were gel purified with the Qiagen kit and reamplified with the Taq-Pwo polymerase mixture, between 5 and 7 g of DNA per 50-l PCR assay mixture was obtained. The 3.2-kb HBV DNA represented about 50% of the total DNA: the rest was nonspecific background. HBV genome populations amplified by two rounds of PCR from a small number of molecules of cloned wild-type HBV DNA as well as from HBV DNA from the serum of a patient worked well in transfection experiments. They expressed HBsAg as well as HBeAg (not shown) and produced replicative HBV DNA intermediates (Fig. 4A , lanes WT-PCR and Patient-PCR). The potential of this system for the analysis of the sensitivity of clinical HBV isolates to antiviral drugs was evaluated by testing the IFN-␣ responsiveness of the amplified HBV genomes. Replication of an amplified wild-type genome population was inhibited by IFN-␣ (Fig. 4A , compare lanes IFN-␣ ϩ and Ϫ), as is known for nonamplified wild-type HBV in stable transfection systems (16) . Thus, a two-step PCR method was established for amplification of HBV genomes from material from patients with low levels of viremia which yields sufficient product for transfection without prior cloning. The amplified genome populations replicate, express viral antigens, and are susceptible to IFN-␣ when transfected into cells.
As shown above, individual amplified DNA molecules are rather frequently rendered completely defective by PCR-introduced mutations. Such drastic effects are not necessarily expected when the whole population of amplified molecules is functionally analyzed. However, amplification may quantitatively change phenotypic features of the amplified DNA population according to the number of mutations (and thus, of defective genomes) that accumulate during PCR. To estimate this effect, a nonamplified, cloned wild-type genome as well as extensively amplified wild-type genomes was transfected and its replication and antigen expression levels were compared. In general, the PCR products produced lower levels of replicative HBV DNA, HBsAg, and HBeAg than the nonamplified genome (Fig. 4A and B, compare lanes WT-PCR and WT) . Interestingly, the levels of replicative HBV DNA were reduced two to three times more than the antigen levels, which is probably a consequence of PCR-introduced mutations.
DISCUSSION
The efficiency of HBV full-length genome PCR as well as the frequency and functional relevance of PCR-introduced mutations in different polymerase assays was evaluated in this study. The Taq-Pwo polymerase mixture was found to be the most sensitive, and it introduced fewer mutations when amplifying low copy numbers. With this assay, about 40% of the replication-competent HBV genomes from a clinical specimen from a patient with a low level of viremia can be expected to retain their replication and antigen expression phenotypes af-ter amplification. Because replication competence was found to be highly sensitive to random mutations, it is a useful marker to identify HBV genomes with few or no PCR-introduced mutations.
Previous studies demonstrated an increase in PCR sensitivity and fidelity if a polymerase that exhibits proofreading activity is combined with an enzyme lacking this activity (2, 9) . Here, we confirmed this by testing Taq and Pwo polymerases alone and combined in the HBV full-length PCR. However, additional enzyme combinations are currently available, and further experiments are needed to test whether they perform similarly to or even better than the Taq-Pwo polymerase system.
Two observations have important implications for the functional analysis of genomes amplified from clinical samples. First, nearly all amplified wild-type genomes either replicated at the authentic preamplification level or were completely defective, and second, the replication competence of an amplified genome correlated with intact HBsAg and HBeAg expression and a low number of artificial mutations. Therefore, it can be expected that the majority of genomes which remain replication competent after amplification show the authentic replication and antigen expression phenotypes and contain no or very few PCR-introduced mutations. Replication-competent genomes in which mutations have accumulated during amplification will most likely be defective and can easily be excluded VOL. 36, 1998 FULL-LENGTH HEPATITIS B VIRUS GENOME PCR 535 from a detailed analysis when one screens first for replication competence.
The identification of replication-defective genomes in sera is not easy. An indication whether a genome is naturally or artificially defective may be provided by determining the type and prevalence of the mutation(s) by sequencing. All artificial mutations found in the amplified genomes in our study were nucleotide changes, and the same one was never found in more than one genome. Therefore, a mutation(s) shared by a substantial virus subpopulation or deletions and insertions is not likely to be PCR derived. Furthermore, the data provided by this study allow a rough estimate of the fraction of naturally defective genomes in clinical specimens. If far more genomes are replication defective than would be expected from artificial mutations after amplification (Fig. 5 shows an estimation of this fraction according to the template number), this indicates a large fraction of naturally defective genomes in the analyzed sample. A first analysis revealed that this is obviously not the case for HBV populations in sera of patients with fulminant hepatitis, as the fraction of genomes which were replication competent after amplification corresponded to the expected level.
The need for analysis of individual genomes can be circumvented if the amplified genomes are directly transfected without prior cloning, as was previously shown for genomes amplified from high-titer sera (13) . As an extension of these previous results we present evidence that this method works even after extensive amplification of a small number of template molecules. However, for correct interpretation of data obtained by the described method one has to take into account that amplification selectively reduces the level of replication compared to that of antigen expression. This is probably the result of PCR-introduced mutations, which affect replication more frequently than antigen expression, as is evident from the analysis of the cloned genomes. This effect need not be considered if data are compared that were obtained with the same HBV DNA preparation analyzed under different conditions, as exemplified here by testing HBV replication with and without the addition of IFN-␣ to the transfected cells. Thus, the PCR product transfection assay may prove particularly useful for monitoring the possible resistance of clinical HBV isolates to antiviral drugs before and during therapy (1, 19, 38) .
From a biological point of view, it is surprising that the replication-competent genomes contained only an average of one artificial mutation. This suggests that the random introduction of very few mutations can severely interfere with HBV replication. This would not be expected, considering the high sequence heterogeneity of HBV, with several genotypes which differ by more than 10% on the nucleotide level (23) . Replication can be affected by mutations which inactivate RNA or DNA elements involved in transcription, pregenome encapsidation, and replication or by mutations which alter the function of the nucleocapsid or HBV polymerase proteins. In two of the defective genomes one of the latter proteins is predictably truncated due to premature stop codons, which explains the replication defect. In most other defective genomes inactivation of the HBV polymerase function is most likely responsible for the replication defect, for two reasons. First, the coding sequence of the HBV polymerase covers about two- 11 final molecules) with Taq or Taq-Pwo polymerases. The fraction of genomes with Յ2 artificial mutations may roughly correspond to the fraction of genomes which remain replication competent after PCR, since most replication-competent genomes will contain either no, one, or two mutations after PCR, according to our experiments (an average of one mutation per genome). Consistent with this assumption, the calculated fractions of genomes with Յ2 mutations (5 and 40% after PCR with Taq polymerase [900 templates] and Taq-Pwo polymerases [90 templates], respectively) are in good agreement with the fractions of replication-competent genomes determined experimentally (12 and 41%). Based on a simplified PCR model the fractions were calculated by using the distribution function of the binomial distribution B(2;n;P gen /2) (see Materials and Methods). n was calculated with N i and N f , and P gen ϭ P pos ϫ 3,200. The error rate, P pos , was experimentally determined for Taq polymerase and the Taq-Pwo polymerase mixture (Table 3) . thirds of the HBV genome, which leads to a high probability that a random mutation will change the amino acid sequence of the HBV polymerase. Consistent with this speculation, most of the amino acid changes in the amplified genomes were found in the polymerase. Second, the HBV polymerase is a multifunctional protein with a function in assembly-encapsidation of RNA-and three enzymatic functions: DNA synthesis priming and DNA polymerase and RNase H activity (22, 26) . All these functions are probably highly susceptible to changes in the protein structure. This speculation is supported by our observation that in three amplified genomes the defect in replication can be attributed to only a few amino acid changes in the polymerase (Fig. 6 ). This interpretation is consistent with a study showing that most of a variety of single amino acid changes rendered the HBV polymerase inactive (27) . In conclusion, our data point to a rather limited sequence flexibility of the HBV genome, probably because of the highly mutation-sensitive polymerase protein encoded by a large part of the genome.
